Virtual Reality Assisted Patient Empowerment: Diagnose ATTR-Amyloidosis And Start Treatment

Launched by HEINRICH-HEINE UNIVERSITY, DUESSELDORF · Jul 3, 2023

Keywords

ClinConnect Summary

This clinical trial is looking at whether using virtual reality (VR) can help patients understand and manage a serious condition called ATTR amyloidosis, which affects the heart. The goal is to see if VR-based education can lead to better diagnosis and treatment rates compared to regular education methods. Many patients in Germany may have this condition without being diagnosed, and this study aims to find out if VR can make a difference in getting the right care.

To participate in the trial, you would need to be between the ages of 65 and 74 and have been referred for evaluation because of unclear thickening in the heart walls, which may suggest cardiac amyloidosis. Unfortunately, people under 18, those currently taking specific medications for this condition, or those with certain health issues like severe vision or hearing impairments cannot join. If you take part, you can expect to learn more about your condition in an engaging way through VR, which could help you understand your health better and possibly start treatment sooner.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • patients who present themselves for assessment of an unclear septal thickening with suspicion of cardiac amyloidosis.
• Exclusion Criteria:
• • 1. \< 18 years
• • 2. Active Medication with tafamidis
• • 3. Cardiovascular Disease
• • 4. highly impaired vision or hearing
• • 5. advanced dementia syndrome
• • 6. epilepsy
• • 7. insufficient language skills